US FDA rebuffs Cornerstone electrolyte disorder drug lixivaptan
This article was originally published in Scrip
Executive Summary
Perhaps it was the fact that investors expected a US FDA rejection following the negative outcome of a September advisory committee meeting – or that Wall Street remained in shock, recovering from Hurricane Sandy – but shares of Cornerstone Therapeutics had only a somewhat mild reaction to regulators calling for more data before approving the company's experimental drug lixivaptan.